CVRx (CVRX) Debt-to-Equity : 0.40 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is CVRx Debt-to-Equity?

CVRx's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.23 Mil. CVRx's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $30.38 Mil. CVRx's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $75.95 Mil. CVRx's debt to equity for the quarter that ended in Dec. 2023 was 0.40.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for CVRx's Debt-to-Equity or its related term are showing as below:

CVRX' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.07 Med: 0 Max: 0.4
Current: 0.4

During the past 5 years, the highest Debt-to-Equity Ratio of CVRx was 0.40. The lowest was -0.07. And the median was 0.00.

CVRX's Debt-to-Equity is ranked worse than
66.06% of 710 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs CVRX: 0.40

CVRx Debt-to-Equity Historical Data

The historical data trend for CVRx's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CVRx Debt-to-Equity Chart

CVRx Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-0.07

0.07

0.40

CVRx Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial												0.07	0.15	0.17	0.19	0.40

Competitive Comparison of CVRx's Debt-to-Equity

For the Medical Devices subindustry, CVRx's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CVRx's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CVRx's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where CVRx's Debt-to-Equity falls into.

CVRx Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

CVRx's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.231	+	30.382)	/	75.947
	=	0.40

CVRx's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.231	+	30.382)	/	75.947
	=	0.40

CVRx (NAS:CVRX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

CVRx Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of CVRx's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

CVRx (CVRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CVRx Inc (NAS:CVRX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

9201 West Broadway Avenue, Suite 650, Minneapolis, MN, USA, 55445

Website

https://www.cvrx.com

CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.

Executives

Johnson & Johnson Innovation - Jjdc, Inc.	10 percent owner	410 GEORGE STREET, NEW BRUNSWICK NJ 08901
Paul Verrastro	officer: Chief Marketing Officer	9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Kevin Hykes	director	2 GOODYEAR, SUITE B, IRVINE CA 92618
Kirk G. Nielsen	director	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Mudit K. Jain	director	C/O TREO VENTURES, 140 WASHINGTON STREET, SUITE 200, RENO NV 89503
Craig E. Palmer	officer: SVP, U.S. Sales	9201 WEST BROADWAY AVENUE, SUITE 650, MINNEAPOLIS MN 55445
Martha Shadan	director	9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
New Enterprise Associates 10 L P	10 percent owner
Nea Partners 10 L P	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Geoffrey B Pardo	director	100 DOMAIN DRIVE, EXETER NH 03833
Jared Oasheim	officer: Chief Financial Officer	9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
John Brintnall	officer: Chief Strategy Officer and Sec	9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Dean Bruhn-ding	officer: VP of Reg. Affairs and QA	9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Liz Galle	officer: VP of Global Clinical Research	9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Nadim Yared	director, officer: Chief Executive Officer	9201 W BROADWAY AVE #650, MINNEAPOLIS MN 55445